Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
1.040
-0.040 (-3.70%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd.
| Country | Israel |
| Founded | 2005 |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel | |
| Phone | 972 5 5433 5665 |
| Website | polyrizon-biotech.com |
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.38 |
| CIK Code | 0001893645 |
| ISIN Number | IL0011814113 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer and Director |
| Nir Ben Yosef | Chief Financial Officer |
| Dr. Tidhar Turgeman | Chief Technology Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Scientific Officer |
| Daphna Avital | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 30, 2025 | 6-K | Report of foreign issuer |
| Jan 23, 2025 | 6-K | Report of foreign issuer |
| Jan 22, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 21, 2025 | 6-K | Report of foreign issuer |
| Jan 15, 2025 | EFFECT | Notice of Effectiveness |
| Jan 10, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 6, 2025 | UPLOAD | Filing |
| Dec 30, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 30, 2024 | 6-K | Report of foreign issuer |
| Dec 19, 2024 | 6-K | Report of foreign issuer |